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E. coli Dihydroorotate Dehydrogenase Reveals
Structural and Functional Distinctions between
Different Classes of Dihydroorotate Dehydrogenases
solic enzymes, while the class 2 enzymes are membrane
associated. The catalytically important base in the active
site differs between the two classes of enzymes, as do
the electron acceptors used by the enzymes. The class
1 enzymes can be further divided into two subtypes,
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lactis, dihydroorotate dehydrogenase A (DHODA) andDenmark
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Sølvgade 83H and their structures have been determined both in the
native state and in complexes with orotate [9–11]. InDK-1307 Copenhagen
Denmark both DHODA and DHODB, a cysteine residue, common
to all class 1 DHODs, serves as the catalytic base.
DHODA is a homodimeric protein composed of two
PyrD subunits, each containing an FMN group andSummary
folded into an / barrel [9, 10]. Fumarate has been
suggested as the natural electron acceptor for DHODAThe flavoenzymes dihydroorotate dehydrogenases
[12, 13]. DHODB is a functional heterotetrameric protein(DHODs) catalyze the fourth and only redox step in the
composed of two heterodimers, each consisting of onede novo biosynthesis of UMP. Enzymes belonging to
PyrD subunit and one PyrK subunit [11, 14, 15]. Theclass 2, according to their amino acid sequence, are
PyrD subunit of DHODB contains the prosthetic FMNcharacterized by having a serine residue as the cata-
group and is structurally similar to the subunits compos-lytic base and a longer N terminus. The structure of
ing DHODA. The polypeptide chains of DHODA and theclass 2 E. coli DHOD, determined by MAD phasing,
PyrD subunit of DHODB both consist of 311 amino acidshowed that the N-terminal extension forms a sepa-
residues, but the identity between the two sequencesrate domain. The catalytic serine residue has an envi-
is only about 30% [8]. The PyrK subunit contains a [2Fe-ronment differing from the equivalent cysteine in class
2S] cluster and an FAD as cofactors and belongs to1 DHODs. Significant differences between the two
the ferredoxin reductase superfamily. The capability ofclasses of DHODs were identified by comparison of
DHODB to use NAD as electron acceptor resides inthe E. coli DHOD with the other known DHOD struc-
the PyrK subunit [15].tures, and differences with the class 2 human DHOD
The sequence identity between the class 1 and classexplain the variation in their inhibitors.
2 enzymes is low (less than 20%). Between the different
class 2 enzymes, the sequence identity increases to a
Introduction minimum of 40% [8]. The Escherichia coli DHOD (DHODC),
a representative of class 2, has a molecular mass of 37
Dihydroorotate dehydrogenases (DHODs) catalyze the kDa and contains one FMN [16, 17]. In class 2 enzymes
oxidation of (S)-dihydroorotate to orotate. This is the a serine residue corresponds to the active site cysteine
fourth step and the only redox reaction in the de novo in class 1 [13], and quinones from the respiratory chain
biosynthesis of UMP, the precursor of all pyrimidine are used as electron acceptors [18, 19]. Compared with
nucleotides. In rapidly proliferating mammalian cells, the the class 1 enzymes, all class 2 enzymes have an ex-
pyrimidine salvage pathways are insufficient to over- tended N terminus. The N-terminal extension of DHODC
come deficiencies in the de novo pathway for nucleotide is short compared with the N-terminal extensions of the
synthesis. Moreover, as certain parasites lack salvage eukaryotic class 2 enzymes, which also carry mitochon-
enzymes, the inhibition of DHODs has turned out to be drial targeting sequences and a segment of residues
an efficient way to block pyrimidine nucleotide biosyn- that may form a helix that could integrate the protein
thesis. This makes these enzymes selective targets for into the membrane [20, 21].
antiproliferative, antiparasitic, and immunosuppresive The overall reaction catalyzed by the DHODs can be
drugs [1–7]. divided into two half reactions. In the first half reaction,
The DHODs can be divided into two major classes on the oxidation of dihydroorotate to orotate is associated
the basis of their amino acid sequences and their cellular with the transfer of a hydride ion to the FMN group.
location [8]. We have changed the terms previously used Electron transfer from FMN to the external electron ac-
to specify the two major groups of dihydroorotate dehy- ceptor, i.e., reoxidation of the FMN group, constitutes
drogenases (DHODs) from family 1 and family 2 DHODs the second half reaction. This second reaction step is
[8] to the more neutral terms class 1 and class 2 DHODs conducted very differently for enzymes belonging to the
to avoid the unintended implication that the two groups two classes and differs also between subclass 1A and
of DHODs have evolved by convergent evolution of dif-
ferent ancestral proteins. Members of class 1 are cyto-
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1B. These differences are connected to the nature of lecular contacts. Judging from the temperature factors,
molecule A is the most rigid, molecules B and E arethe electron acceptors and how they interact with the
reduced FMN; they may also depend on the oligomeric comparable, and molecule D, with the remarkably higher
global B factor, is the most flexible.state of the DHODs. The variations in the catalytic mech-
anism of DHODs from different organisms make them The crystals were grown in a high concentration of
formate ions (3.5 M), influencing the binding of orotatesuitable drug targets, as DHODs from one species (e.g.,
a parasite) may be selectively inhibited without affecting in the active site. Orotate is only bound in molecule A.
In the other three protein chains composing the asym-the DHOD from another organism (the host).
In this paper we present the structure of the E. coli metric unit, two or three formate ions replace the orotate
ion in the active site (Table 1). The replacement of orotateDHOD (DHODC) cocrystallized with the reaction product
orotate. The structure was solved using the MAD phas- with formate ions, which can fulfill almost the same hy-
drogen bond pattern as orotate, must have taken placeing technique on crystals grown from the selenomethio-
nine-substituted protein. The E. coli enzyme was ex- after the crystals were formed, as we would have ex-
pected a random distribution of formate and orotatepressed, purified [13], and crystallized [22] with its N
terminus intact. The structure has recently been deter- ions if the complexes had been formed in solution. Sub-
stitution of orotate with formate is in accordance withmined for another DHOD belonging to class 2, human
DHOD [23] in a truncated form, where the first residues the higher flexibility and the easier access to the active
site for molecules B, D, and E. Two orotate ions arewere removed from its N terminus to make it of a similar
length to the E. coli enzyme. Among the class 2 DHODs, hydrogen bonded to the positively charged N-terminal
amino group of molecules A and D, with the ion boundthe sequence identity is generally low for their N-terminal
part. As the binding site for the electron acceptor has to molecule A adopting two different positions. Unless
otherwise stated the subsequent structural description isbeen proposed to be associated with the N terminus,
this part of the structure has been examined for struc- based on the well-defined and most rigid molecule A.
Overall Foldtural differences that can explain the variation in inhibi-
tion of the different class 2 DHODs with respect to the DHODC is a monomer (Figure 1), in contrast to the struc-
tures of the DHODs from class 1: DHODA is a homodi-second substrate, the electron acceptor [24–26]. The
knowledge of the structures of four different DHODs mer, and DHODB is a heteroteramer [9, 11]. The DHODC
monomer contains 11  helices, 4 310 helices, and 13 that are representatives of the two classes has given
the basis for a thorough comparison, which enabled strands (Figures 1 and 2). Similar to other DHOD struc-
tures (DHODA [9], DHODB [11], and human DHOD [23]),us to identify the structural characteristics that can be
related to the variation in substrate affinity between and DHODC folds into an / barrel. The barrel is comprised
of eight parallel  strands surrounded by twelve helices,within the two classes of DHODs. On the basis of this
analysis and previously reported kinetic data, we have with FMN and orotate situated at the top of the barrel.
The remaining five strands form two antiparallel sheets,been able to propose a reaction model for the first half
reaction, which is shared by the members of this family one located at the top of the barrel covering FMN and
the other located at the bottom of the barrel. In additionof enzymes.
to this main barrel, DHODC contains a second domain
situated at the side of the barrel formed by the extended
Results and Discussion N terminus that folds into two  helices and one 310 helix
(Figure 1).
Structure of the E.coli DHOD The N-Terminal Domain
Crystal Packing To examine the role of the N-terminal domain for the
The asymmetric unit of the crystal contains four DHODC function of E. coli, we generated DHODC proteins with
molecules, labeled A, B, D, and E. Two of the molecules deletions of the N-terminal residues from 2 down to 40
(B and E) are related by a noncrystallographic 2-fold axis by PCR as described in Experimental Procedures. The
and are interacting through their N-terminal domains. truncated proteins could be produced in large quantities
These interactions can explain why the protein in solu- in E.coli, as judged from the strong yellow color of the
tion can behave like a dimer [13], although it is easily extracts, but they were generally unstable, as the apo
recognized as monomer in the crystal. The four mole- proteins quickly precipitated and FMN remained in solu-
cules display some small, but significant, differences tion. A truncated protein, lacking residues 2–30, was
and were treated as independent molecules in the final sufficiently stable to attempt purification by the protocol
stages of the refinement. These structural differences described by Bjo¨rnberg et al. [13]. In contrast to wild-
can be attributed to variations in the crystalline environ- type DHODC, the protein did not adsorb to the hy-
ment of the four molecules, differences that also influ- drophobic phenyl Sepharose column. Instead, an almost
ence the overall temperature factor of the individual homogenous preparation of the protein could be ob-
molecules (Table 1). Examination of the crystal contacts tained by chromatography on a Q6 column and manual
with ACT [27] showed that the A, B, and E molecules collection of the yellow protein band that passed
are in contact with six other molecules, whereas D has through the column during development of the salt gra-
contacts to five other molecules. The number of intermo- dient. This protein had near to wild-type DHOD activity,
lecular contacts (less than 5 A˚) correlates well with the with molecular oxygen as the electron acceptor. With the
temperature factors: A has 1175 contacts, E has 1143 addition of dichloroindophenol to the assay, the activity
contacts, and B has only 913 contacts, whereas D, with increased 40-fold for the wild-type DHOD, but only
2-fold for the truncated enzyme. During storage for 4the highest temperature factors, has only 598 intermo-
E. coli Dihydroorotate Dehydrogenase
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Table 1. Refinement Statistics for the Structure of the E. coli DHOD
R (%) 17.7
Rfree (%) 21.7
Resolution (A˚) 20–2.5
No. of water molecules 1043
B water (A˚2) 36.9
Rms bonds (A˚) 0.006
Rms angles () 1.26
Rms dihedrals () 22.4
Rms improper () 0.95
Molecule A Molecule B Molecule D Molecule E
No. of atoms 2595 2595 2586 2601
No. of FMN atoms 31 31 31 31
No. of orotate1a atoms 11
No. of orotate2b atoms 22 11
No. of formate atoms 9 6 9
B main chain (A˚2) 21.1 28.8 36.7 25.7
B side chain (A˚2) 24.0 31.7 39.0 28.9
B FMN (A˚2) 16.4 20.1 29.6 19.1
B orotate1a (A˚2) 21.4
B orotate2b (A˚2) 68.3 76.6
B formate (A˚2) 51.0 46.0 41.0
Individual values are given for the four molecules in the asymmetric unit.
a Orotate1 refers to the orotate bound in the active site.
b Orotate2 refers to the orotate bound at the N terminus.
days at 4C, the protein gradually lost all its activity, hydrophobic (cyan) and charged (red). The solvent-
exposed part of the domain does not possess an excesswhile the apo protein precipitated, and FMN stayed in
solution (data not shown). In a previous study truncated of hydrophobic residues, and there is no concentration
of charged residues oriented toward the barrel. Thisversions of DHODC, in which the first 38, 39, or 41 resi-
dues of DHODC were replaced by the first 7 residues distribution of residues on the surface of the N-terminal
domain would make it possible for the enzyme to adhereof -galactosidase (B. Bunke and K.F.J., unpublished
data), it was found that these truncated versions of to the membrane, but makes it very unlikely that it is
integrated into the membrane. This role of the N-terminalDHODC retained a few percent of activity and that they
did not adhere to the bacterial membranes, as judged domain is also supported by the results from the search
for transmembrane helices with the TMHMM programfrom experiments with “minicell.” These results made
us conclude that the N-terminal domain of DHODC is [28], which did not reveal any transmembrane segments
in the sequence of DHOD from E. coli. In the humanimportant for (1) its interaction with the respiratory (hy-
drophobic) quinones, (2) the strong hydrophobic nature DHOD only the region of the sequence that was removed
prior to crystallization possesses indications for a trans-of DHODC in the presence of salt, and (3) the attachment
of the protein to cellular membranes. Furthermore, the membrane helix. The N terminus of the human DHOD is
illustrated in Figure 3C. The similarity between the N-ter-results also reveal that the N-terminal domain is essen-
tial for the stability of the catalytic / barrel domain of minal domain of the two class 2 DHODs is exemplified
in the central hydrophobic patch between the two the protein.
The two  helices and the short 310 helix that form the helices identified as the binding site for the inhibitors of
the human enzyme. However, as illustrated in FiguresN-terminal domain are connected to the / barrel by
a long loop, which can be partially superposed to the 3B and 3C, they do show distinct differences both in
the shape of the patch and in its delineation by sideN termini of the class 1 enzymes (Figure 4). The structure
seems to be stabilized by interactions between the first chains.
None of the inhibitors that bind to the human enzymeN-terminal helix of the small domain and the two C-ter-
minal helices located in the main barrel. These interac- inhibit the E. coli enzyme. Liu et al. attributed this differ-
ence to steric hindrance caused by substitution oftions involve only one side of the N-terminal helix, leav-
ing the solvent-oriented part disposed for membrane Val134 residue in the human enzyme with Leu100 in
DHODC [23]. From a comparison and superposition ofinteraction. Similar structural features were reported for
the truncated human DHOD lacking the proposed trans- the N-terminal domains of the two structures, we could
identify several other differences that also could explainmembrane part of its N terminus. The structure of the
human enzyme in complex with two different inhibitors why inhibitors act differently on the two enzymes. Of
the nine residues involved in binding of inhibitors of the[23] showed that its N-terminal domain hosts the qui-
none binding site. Our deletion experiments described human DHOD, only four were conserved in DHODC:
His19, Arg102, Tyr318, and Pro326 (Figure 2). Amongabove support that the N terminus of the E. coli enzyme
serves a similar function. these residues only one is localized in the N-terminal
domain. Apart from the side chains of Leu10 (DHODC)Two views of the N terminus in DHODC are shown in
Figures 3A and 3B, with the residues color coded as and Leu46 (human DHOD), which superimpose well, sev-
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known DHODs, e.g., the human enzyme, the other mem-
ber of class 2, and the two class 1 DHODs from Lacto-
coccus lactis. The structural similarity within each class
of DHOD is reflected in the rms values resulting from
the alignment of the C atoms of the PyrD subunits [29]
(DHODC ↔ DHODA, 249 pairs, rms  1.62 A˚; DHODC ↔
DHODB, 234 pairs, rms  1.32 A˚; DHODA ↔ DHODB,
269 pairs, rms  1.87 A˚; DHODC ↔ human DHOD, 282
pairs, rms0.89 A˚). Using DHODC as a representative of
a class 2 DHOD, we performed a structural comparison
between the complexed and uncomplexed structures
of the PyrD subunits of the class 1 enzymes DHODA
and DHODB. In all three structures the FMN group and
the active site are covered by the so-called active site
loop, which contains the catalytic base. Only the DHODB
enzyme has been reported in two states, with open and
closed conformations of the active site loop [11], which
correspond to different interactions with the PyrK subunit.
The most significant difference between DHODC and
the PyrD subunits of the two enzymes from Lactococcus
lactis is the N-terminal domain present in DHODC. This
domain, together with the active site loop, shields the
orotate and the FMN group from the solvent in DHODC,
while the formation of dimers of the PyrD subunits in
DHODA and DHODB effectively shield their active sites,
which appear less protected in their monomers, de-
picted in Figure 4. In contrast the DHODB and DHODA
structures have a C-terminal elongation of about 20
amino acids relative to DHODC. Notable differences be-
tween class 1 and class 2 enzymes are also observed in
other regions of the structures. The segment in DHODC
comprised by residues 142–153, situated after 3 and
including helix 3a, is significantly longer than the corre-
sponding regions in DHODA (102–106) and DHODB
(107–111). This segment faces the loop, which contains
the catalytic base (DHODC, 173–184; DHODA, 128–139;
DHODB, 133–145) and is of almost identical length in
the three structures. The longer segment in DHODC
introduces a steric hinderance, which makes it impossi-
ble for the active site loop to be completely open, as in
the DHODB structure, but it is able to open sufficiently
for orotate to enter. Two other regions in DHODC, seg-Figure 1. The DHODC Monomer Color Coded to Illustrate the Differ-
ment 201–212, including part of the 4 helix, and theent Secondary-Structural Elements
loop 248–264, are different in size, secondary structure,The three dark blue-shaded helices form the N-terminal membrane-
and orientation from the corresponding parts in bothassociated domain. The FMN (yellow) and orotate (orange) mole-
cules are drawn as sticks. Front view (A); side view (B). DHODA and DHODB.
A standard sequence alignment suggested that
DHODC does not possess a residue that is equivalenteral distinct differences between the two structures can
to the catalytically important Lys43 in DHODA foundbe observed. The space occupied by Gln47 in human
at the end of  strand 2 [9]. Nevertheless, the structuralDHOD is filled by Phe11 in DHODC, Thr22 replaces Ala59
alignment revealed that Lys66 in DHODC occupies the(human DHOD), and Arg7, which extends into the solvent
same spatial position and fulfills the same function asregion in DHODC is, in the human DHOD, replaced with
Lys43 in DHODA found at the end of 1 [30], thoughMet43 interacting with the inhibitor. Furthermore, Leu64
they are located in different parts of the polypeptidein DHODC occupies the space filled by Phe98 in human
chain. Lys66 in DHODC is found between the first twoDHOD. These changes modify the local charges and the
structural elements of the / barrel (1 and 1). In ordersize of the binding site and can explain why the inhibitors
to make Lys66 adjacent to the FMN group, this segmentof the human enzyme do not act on DHODC.
adopts a conformation that differs significantly from the
corresponding region (20–39) in the DHODA, thoughStructural Relations to Other Dihydroorotate
both structures contain a small  helix, 1 (DHODC,Dehydrogenases
70–77; DHODA, 25–35), in this sequence region. DHODBBackbone-Based Structural Comparison
is slightly different in this segment (25–44), as it con-Knowledge of the structure of DHODC has opened pos-
sibilities to make structural comparisons to the other tains two 310 helices (32–36 and 38–42). In the uncom-
E. coli Dihydroorotate Dehydrogenase
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Figure 2. Sequence Alignment of DHODC and the Human DHOD
Residues shown in magenta are conserved between the two enzymes. Secondary-structural elements in DHODC, green; those in human
DHODB, blue. The symbol  is used for both  helices and 310 helices. This figure was prepared with ALSCRIPT [48]
plexed DHODB structure, Lys48, equivalent to Lys 43 in completely conserved aspargine residues involved in
the binding of orotate have identical interactions in theDHODA, is turned away from FMN, pointing toward the
PyrK subunit [11]. The same movement of the Lys in known structures (Figures 5E–5G).
Some small variations are observed by the substitu-DHODA would require a significant rearrangement in the
region 20–39 to avoid unfavorable steric contacts. In tion of Ser44 (DHODA) with Thr86 in DHODC. This in-
cludes an additional cis-peptide bond, between resi-DHODC the N-terminal domain hinders an equivalent
rearrangement. dues 85 and 86, that is not observed in the DHODA or
DHODB structures. The backbone NH group of Thr86Comparison of the Active Sites
The hydrogen bond interactions connecting FMN to the forms a hydrogen bond to FMN O4 (Figure 5A). The latter
interaction is preserved in DHODB (Figure 5C), whichprotein are illustrated in Figure 5A. The conformation of
the tail of FMN in DHODC is stabilized by an intramolecu- contains an alanine residue in this position (Ala49). This
residue cannot make the side chain-FMN interactionlar hydrogen bond between a phosphate oxygen and
O4 from the ribityl group, as in the other DHODs. The seen in DHODC and DHODA. It is noteworthy that Lys66
and Thr86 serve a similar function to two adjacentphosphate group also forms hydrogen bonds to the
backbone of the two conserved glycines (Gly297 and residues, Lys43-Ser44 in DHODA and Lys48-Ala49 in
DHODB. The presence of Tyr318 close to the FMN repre-Gly268), Ser319, and Tyr318. The ribityl O3 and O2
groups also have interactions that are similar to those sents a major difference between the class 1 and 2
DHODs. Its side chain is stacked on the re face of theobserved in the other DHODs, namely, interactions to
the backbone carbonyl groups from Thr245 and Ala62. FMN group on the opposite side of the binding site
for orotate, and the prominent fluorescence quenchingThe isoalloxazine ring of the FMN is hydrogen bonded
to the backbone NH and side chain of Thr86 and the observed for the E. coli enzyme can be attributed to
this stacking interaction [13], which could also facilitateside chains of Lys66 and Lys217. The latter residue also
interacts with ribityl oxygens O2 and O3. This hydrogen electron transfer. In this position, the class 1 DHODs
have a highly conserved glycine, which provides muchbond pattern is seen in all four DHODC molecules. How-
ever, molecules B, D, and E, where orotate is replaced more space around the dimethyl benzene moiety of FMN
(Figures 5B–5D).by formate, contain an additional hydrogen bond be-
tween the FMN O2 and N	2 of Asn139. In Figure 5E we The different DHODs display some small, but signifi-
cant, differences in the hydrogen bond interactions ofshow the interactions of the orotate ion bound in the
active site of molecule A. The carboxylate group is hy- the lysine residue adjacent to N1 of the isoalloxazine
ring: DHODA, Lys164; DHODB, Lys170; DHODC, Lys217.drogen bonded to the backbone NH groups from Gly114
and Phe115 and to the side chains of Asn177 and Lys66. In DHODC and DHODA this residue makes hydrogen
bonds to FMN O2, N1, O3, and O2. In the orotateThe hydrophilic moiety of the ring interacts with the side
chains of Asn172, Asn111, Asn246, and Thr247. The four complex of DHODB, Lys170 is only hydrogen bonded
Structure
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Figure 4. C Backbone Alignment of the Different DHODs: DHODC,
DHODA, and DHODB
DHODC, chartreuse; DHODA, coral; DHODB, purple. C and N termini
are marked with a C or N in the corresponding color. The main
differences are observed in the longer N terminus for DHODC and
the longer C termini of DHODA and DHODB.
to N1, and O2 is hydrogen bonded to Asn104, instead.
In its open uncomplexed form, Lys170 has hydrogen
bond contact distances to Met247 S
 and FMN O3.
Thus, in the open uncomplexed form of DHODB, there
are no direct interactions between the isoalloxazine ring
and the positively charged lysine residues in its environ-
ment, which would tend to decrease the redox potential,
whereas there are direct interactions in the closed con-
formation, which will increase the redox potential and
thereby favor electron transfer. These small differences
in the environment of the flavin groups may play a role
for the adjustment of the redox potential of the FMN
group, so it is able to transfer electrons to different
partners in the three enzymes, as it is observed for other
flavin enzymes [31].
The orotate bound in DHODC has interactions that
are remarkably similar to those in DHODA and DHODB,
but some small variations are observed in the hydrogen
bond arrangements that connect the surrounding resi-Figure 3. Structural Features of the N-Terminal Domain
dues. In DHODC the backbone NH group of Met113 isSide view (A); front view of the DHODC N terminus (B); front view
of the human DHOD (Protein Data Bank code 1d3g) (C). Only the hydrogen bonded to the side chain O	1 of Asn111 (Fig-
first 40 residues corresponding to the extension, compared to family ure 5E); a similar interaction is seen in DHODA, but the
1 enzymes, are shown with full side chains and color coded ac- backbone NH group is also hydrogen bonded to the
cording to the following criteria: charged residues (Asp, Glu, Lys,
orotate carboxylate group (Figure 5F). In DHODB, Ile74and Arg), red; hydrophobic residues (Val, Leu, Ile, Trp, Tyr, Phe, and
is found in an equivalent position, and neither of itsMet), cyan. (B) shows that the three helices form a patch that is
backbone atoms is engaged in similar interactions.surrounded by hydrophobic residues and have charged residues
oriented toward the solvent. This cavity has been shown to be the The residue preceding the Cys/Ser catalytic base is
binding site for quinone analog inhibitors in the human DHOD struc- a totally conserved serine residue (DHODC, Ser174;
ture [23], but, as seen in (B) and (C), nonconserved residues delineate DHODA, Ser129; DHODB, Ser134). The position and ori-
the patch. The figure was made with GRASP [49].
entation of its side chain are conserved between
DHODC, complexed and uncomplexed DHODA, and
DHODB with the loop closed. It is the first amino acid
that changes conformation when this loop is open in
E. coli Dihydroorotate Dehydrogenase
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Figure 5. The Environment of the FMN Group
Hydrogen bonds formed between the protein moiety, and the FMN or the orotate is indicated as stipulated lines. FMN: DHODC (A); DHODA
(B); DHODB open loop (C); DHODB closed loop (D). Orotate: DHODC (E); DHODA (F); DHODB (G). It should be noted, however, that the part
of the DHODB structure involving Asn 137 is not well defined.
DHODB, which could indicate that this serine plays a lysine residue interacting with N1 of the FMN group
(DHODC, Lys217; DHODA, Lys164; DHODB, Lys170).role as a hinge in the opening of the active site loop.
This suggestion is reinforced by its hydrogen bond inter- Furthermore, the backbone carbonyl of the serine in
DHODC forms hydrogen bonds to the side chain ofactions. The backbone NH and side chain of this Ser are
hydrogen bonded to the side chains of two aspargines Arg182. These interactions are all of a nature that en-
sures contact from the active site loop to FMN andinvolved in orotate binding in DHODC (Asn172 and
Asn246), DHODA (Asn127 and Asn193), and DHODB orotate. The significance of these interactions is re-
flected in the difference in trypsinolysis seen with and(Asn132 and Asn197). The side chain makes an addi-
tional hydrogen bond to the backbone carbonyl of the without orotate in the active site. The peptide bond be-
Structure
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in this region, allowing the side chain of Gln138 to be
oriented toward the solvent in the same direction as
Arg182 in DHODC (Figure 6). A pKa value of 9.5 was
assigned to the catalytic base from rapid kinetics studies
of DHODC [32]. At a first glance it appears enigmatic how
a serine residue can have a pKa value of this magnitude.
However the arrangement described above, with three
hydrophilic groups containing four protons engaged in
hydrogen bonds to three donors in a very hydrophobic
environment, does not resemble the interactions of a
serine in aqueous solution. The hydrogen bond pattern
of the three hydrophilic groups creates a proton relay
system, and one can understand the lowering of the pKa
value by being part of a system having one proton in
excess. Introducing the negatively charged carboxylate
group from orotate close to this proton relay system
should favor a proton transfer to orotate from either the
serine residue or the water molecule and, in this way,
create a catalytic base that can initiate the reaction.
In the DHODB structure with an open loop, Cys135 is
found in the same position as Leu181 (DHODC), which
is turned inwards compared with that in the DHODA/
DHODB structures. So, an opening of the active site
loop in the DHODC structure, as in the DHODB structure,
would again (see above) not be possible because of the
orientation of Leu181.
Figure 6. Active Site Loops in the DHODs, Drawn as in Figure 5
Alignment of DHODC (chartreuse) and DHODA (coral) around the
Reaction Mechanismcatalytic active residue Cys130 (DHODA) and Ser175 (DHODC). Sub-
The above analysis showed that the environment of FMNstitution of Leu71 (DHODA) with Phe115 (DHODC) and Gln138
and orotate is very alike in all known structures of(DHODA) with Leu181 (DHODC) represent the most obvious differ-
ences. The later replacement involves a turn of the main chain, as DHODs, suggesting that the first half reaction, the oxida-
Leu181 is oriented toward the active site, Ser, while Gln138 stretches tion of dihydroorotate to orotate and the reduction of the
into the solvent. FMN group, follows the same overall reaction scheme
(Figure 7) in the class 1 and 2 enzymes. Only the tetra-
meric enzymes belonging to subclass 1B (DHODB) dis-tween Arg182 and Thr183 is extremely sensitive to tryp-
sin; however, the presence of orotate exerts a strong play some variations within this scheme.
The model for the reaction is described as separateprotective effect [13]. In DHODB and DHODA the Ser
backbone carbonyl forms a hydrogen bond to a water steps, but it should be noted that it could equally well
take place in a concerted way [33]. First, dihydroorotatemolecule, which also is hydrogen bonded to the back-
bone carbonyl groups of Ser194 (DHODA) and Thr198 (DHO) is attracted into the active site and bound in a
highly specific orientation. The active site loop in(DHODB), both involved in orotate binding. Only the hy-
drogen bond between Ser134 NH and Asn132 O	1 is DHODB can adopt an open and closed conformation
[11], facilitating the access to the active site, a move-conserved in the structure of uncomplexed DHODB with
the open loop, and its backbone carbonyl and O
 are ment that has not been seen in any of the other struc-
tures. A similar movement does not appear possible inhydrogen bonded to water. The water molecule bound
to O
 further interacts with the carbonyl of Thr 198. DHODC because of steric hindrance.
In DHODB, Lys48 (Figures 5C, 5D, and 5G), corre-The proposed catalytic base (Ser175) in DHODC is in
a much more hydrophobic environment than the equiva- sponding to Lys1 (Figure 7), changes its position from
the orotate bound to the free structure. In the free struc-lent Cys residue in the class 1 enzymes (DHODA, Cys130;
DHODB, Cys135). In both DHODC and human DHOD ture, where the active site loop is open, Lys48 is oriented
toward the [2Fe-2S] cluster of the PyrK subunit. In the[23] the Ser-OH group is engaged in two hydrogen
bonds, one to the backbone NH group of Asn177 and the complexed structure the loop is closed, and Lys48 binds
to FMN and to the carboxylate group of DHO, similarlyother to a water molecule (W191). This water molecule
stacks on the aromatic ring of Phe115 and is hydrogen to the way it binds in DHODA and DHODC. We have
therefore proposed [11] that, in the subclass 1B en-bonded to O
 of Thr178, a residue highly conserved in
all class 2 enzymes. Apart from these interactions the zymes, this lysine plays a role for the electron transfer
between the FMN and [2Fe-2S] cluster, in addition toactive Ser is more shielded than the Cys in DHODA
(Figure 6). This is caused by two substitutions, Phe115 being involved in the binding of orotate.
The catalytic residue that abstracts the proton from(DHODC) replacing the Leu71 in DHODA and Leu181,
which points toward Ser175 in DHODC, substituting the C5 of DHO, must first be deprotonated. As described
above the proposed catalytic serine residue is in ahydrophilic Gln138 in DHODA. This last substitution in-
cludes a difference in the conformation of the main chain unique environment that would favor the release of a
E. coli Dihydroorotate Dehydrogenase
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Figure 7. Mechanism of the First Half-Reac-
tion Step Common for All DHODs
Schematic drawing of the proposed reaction
mechanism for the first half reaction, the oxi-
dation of DHO to orotate. Events observed
only in the class 1B (DHODB) structure, blue;
H bonds observed only in class 2 (DHODC)
and class 1A (DHODA), red.
proton. There are no residues in its environment that After this step the mechanism diverges for the en-
zymes belonging to the different subclasses, as they allobviously can deprotonate the catalytic Ser, and, since
the substrate and effective inhibitors all contain a nega- use different electron acceptors. Fumarate, the natural
acceptor for subclass 1A [34], has to replace orotatetive charge, we find it likely that the deprotonization is
substrate induced, in agreement with previous sugges- in the binding site, and the opposite reaction, hydride
transfer from FMN to fumarate, takes place. In the sub-tions [8, 10, 13, 33]. In the known structures orotate is
situated with its carboxylate group close to the -SH or class 1B enzymes represented by DHODB, one electron
transfer reaction passes the electrons from FMN to the-OH group of the active site base (DHODC, O
-O9 
4.22 A˚; DHODA, S
-O9  4.43 A˚; DHODB, S
-O9  FAD in the PyrK subunit via the [2Fe-2S] cluster and
further to NAD, the final electron acceptor that binds4.43 A˚). Substrate-induced abstraction of the proton
from the catalytic base seems to be common to both close to FAD. The class 2 enzymes use quinones as
electron acceptors; they bind in the hydrophobic pocketclasses. In all known structures the catalytic base is
positioned to facilitate abstraction of the DHO C5 proton. created by the N terminus. The stacking of a tyrosine
residue with the FMN group in the class 2 DHODS repre-The subsequent transfer of a hydride ion from C6 to FMN
N5 is also spatially favorable and results in the formation sents another noteworthy difference between the two
classes of DHODs. We find it likely that it could play aof a double bond between C5 and C6. We have noted
that the residues involved in orotate binding are of a role in electron transfer to the second substrate.
Not only the nature, but also the activation, of thenature that would stabilize the carbanion [30, 34]. The
negative charge on the isoalloxazine group created by catalytic base differs between the two classes of en-
zymes. In the class 1 enzymes the cysteine -SH groupthe hydride transfer is balanced through interactions with
a second lysine (Lys2; Figure 7). does not have any hydrogen bond partners in the sur-
Table 2. Data Collection Statistics for the SeMet MAD Data Set Used to Solve the Structure of the E. coli DHOD
1 (0.9700 A˚) 2 (0.98100 A˚) 3 (0.98125 A˚)
Resolution (A˚) 2.5 (2.54–2.50) 2.5 (2.54–2.50) 2.5 (2.54–2.50)
No. of unique reflections 75,583 75,832 75,731
Rsym (%) 8.5 (3.4) 8.1 (24.2) 8.1 (26.7)
Rano (%) 5.2 (22.0) 5.4 (19.3) 5.3 (21.3)
Completeness (%) 98.0 (84.6) 96.9 (70.8) 97.1 (73.1)
Redundancy 8.2 8.5 8.4
I/(I) 16.1 (3.5) 15.5 (3.4) 15.9 (3.2)
BWilson (A˚2) 37.7 37.8 38.3
The values in parentheses refer to the last resolution range.
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rounding residues, as it is situated in an empty pocket. The structural knowledge about different DHODs is
When DHO enters this pocket, it seems probable that important, as it provides insight into the reaction mecha-
the -SH group forms a hydrogen bond with the carboxy- nism of a fundamental biological process, a knowledge
late group of DHO, leading to a subsequent deprotona- that is of high value in the development of new drugs.
tion of the -SH group. The activation scheme in the class The differences identified through structural compari-
2 enzymes is less obvious. The hydrophobic environ- son can be exploited for producing drugs of higher spec-
ment of a unique hydrogen-bonded system could be ificity and effectiveness.
the reason for the lowering of the pKa of the catalytic We have previously determined the structures of the
base in DHODC to 9.5 [32]. Both known class 2 struc- dihydroorotate dehydrogenase A of L. lactis (DHODA),
tures contain a water molecule that makes hydrogen which is a representative of the class 1A enzymes [9] and
bonds to the catalytic Ser and the side chain of Thr178 dihydroorotate dehydrogenase B of L. lactis (DHODB), a
and stacks with the aromatic ring of Phe115. These representative of the class 1B enzymes [11]. In this paper
interactions could be seen as an activation scheme for we describe the structure of a representative of class
the Ser O
-H bond, which is weakened enough to let 2, the Escherichia coli dihydroorotate dehydrogenase
the O
 deprotonate the C5 of DHO or, alternatively, as (DHODC). The overall fold of this enzyme is very similar
an activation of the water molecule. to the / barrel structure seen in other DHOD struc-
tures. To explain the functional differences between the
Biological Implications DHODs, we have carried out a detailed structural com-
parison between DHODC and the other known DHOD
The biosynthesis of UMP is essential for the synthesis structures. The comparison of class 1 and class 2 struc-
of all forms of nucleic acids, RNA or DNA. The de novo tures has revealed a large structural similarity in the
biosynthetic route for UMP is common for all biological FMN and orotate binding sites, allowing us to propose
species, and some are also able to produce UMP by a common mechanism for the first half reaction carried
the salvage pathway. In rapidly proliferating cells the out by this family of enzymes. In addition to this common
pyrimidine requirement cannot be met by the salvage mechanism, we have been able to describe how charac-
pathway, making the de novo pathway an attractive teristic structural differences between the enzymes from
target for inhibition. The fourth step of the UMP biosyn- the various classes allows each enzyme to fine-tune its
thesis is the only redox reaction and the only step that is redox potential and to adapt to its specific electron
catalyzed by a monofunctional enzyme, dihydroorotate acceptor. Furthermore, the Ser residue identified as the
dehydrogenase (DHOD), in all species and never part of catalytic base is in a more hydrophobic environment
a multifunctional polypeptide. Furthermore, the DHODs than the corresponding Cys in the class 1 enzymes,
from different organisms display significant functional and a movement of the active site loop, as observed in
variations that make them attractive targets for the de- DHODB, appears impossible in the class 2 DHODs.
velopment of drugs to be used in the treatment of dis- The DHODC structure has also enabled a comparison
eases either involving rapid cell proliferation, like cancer between class 2 enzymes from different species, focus-
or rheumatoid arthritis, or in situations in which the host ing on the role of the extended N terminus, which is a
is infected by another species, such as malaria. On the special feature of this class of enzymes. The first 40
basis of their amino acid sequence and the electron N-terminal amino acid residues are responsible for the
acceptor used in vivo, the DHODs can be divided into association of the protein to the biological membranes
at least two classes. The soluble enzymes from class 1 and for channeling the electrons to the respiratory qui-
are found in gram-positive bacteria, archaea, and some
nones in the membrane. The three helices of this domain
lower eukaryotes. This class can be further subdivided
generate a hydrophobic cavity, suitable for binding hy-
into class 1A and class 1B. The Trypanosome (sleeping
drophobic compounds. In the structure of human DHOD,
sickness) and Crithidia parasite DHODs, for instance,
this domain has been shown to bind the antiproliferativebelong to class 1A, while many gram-positive bacteria,
reagent brequinar and a decomposition product of leflu-like Clostridia (food poisoning), have DHODs belonging
nomide [23]. The latter has been approved as a prescrip-to class 1B. The class 2 DHODs, which are membrane-
tion drug for the treatment of rheumatoid arthritis [35].associated or -bound, are prevalent in the mitochondria
These compounds are strong inhibitors of mammalianof most eukaryotic organisms and in gram-negative bac-
DHOD activity [4], but very weak inhibitors of the E. coliteria. Different subclasses have not been identified
enzyme [24, 26]. The difference in the inhibition profileamong the class 2 enzymes, although those of eukary-
is likely to be due to a large variation in the amino acidotic origin all seem to possess a transmembrane helix
sequences of the N-terminal domain of the class 2 en-near the N terminus, which is absent from the enzymes
zymes [21]. The fold, but not the sequence, of theof bacterial origin. The class 2 enzymes also exhibit
N-terminal domain of DHODC resembles the corre-significant variations in their response to the inhibitors,
sponding domain of the human DHOD. The comparisonwhich bind in the hydrophobic electron acceptor site
of the two structures identified the local structural varia-in the N-terminal segment of the proteins. This great
tions that explain the difference in inhibition profile.diversity among the DHODs has made it possible to use
All the results presented here are valuable in the de-inhibitors of DHOD activity to selectively retard growth
sign of inhibitors that selectively interfere with the activ-and proliferation of some organisms (parasites) or rap-
ity of certain members of the enzyme family, while leav-idly growing cells without interfering with the growth of
other organisms (hosts) or tissues. ing the others unaffected [25].
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Experimental Procedures and strongly yellow band. The protein was eluted with a gradient
(50 ml) from 0 to 0.3 M sodium chloride in 50 mM sodium phosphate
(pH 7.0) containing 0.1% Triton X-100. During development of thePreparation of Selenomethionyl (SeMet)-Labeled
Dihydroorotate Dehydrogenase gradient, the enzyme migrated as a narrow and sharp yellow zone,
which was collected manually as it appeared from the column. TheSeMet-labeled dihydroorotate dehydrogenase was prepared from
the E.coli strain SØ6735 (rph-1 metA recA56 srl::Tn10/F’lacIq1Z::Tn5 ) enzyme survived for 4 days in the refrigerator, and only few experi-
ments could be made with it.transformed with the expression vector pAG1, in which the pyrD
gene is transcribed from the lac repressor-controlled PA1/04/03 pro-
moter [13]. SØ6735 is a derivative of the strain DL41 (rph-1 metA), Crystallization
which has been used to prepare SeMet proteins in E. coli [36, 37]. Prior to crystallization the protein was dialyzed against a solution
The recA56 mutation was introduced in DL41 by cotransduction with containing 25 mM NaH2PO4 (pH 7.0), 100 M EDTA, 1mM DTT, and
the srl::Tn10 mutation to avoid homologous recombination between 10% glycerol. After dialysis the protein was aliquoted and stored
plasmid-borne and chromosomal pyrD genes. The FlacIq1Z::Tn5 at 20C. The crystals were grown as sitting drops composed of
episome, which causes overproduction of the lac repressor, was 2.5 l reservoir and 2.5 l protein solutions suspended over 600 l
introduced in the strain in order to keep transcription from the PA1/04/03 reservoir solution. The crystallization conditions previously reported
promoter repressed until induction by addition of isopropyl--D- for the native enzyme [22] had to be refined for the SeMet-substi-
thiogalactoside (IPTG) [38]. The cells were grown with vigorous aera- tuted enzyme because of the decreased solubility of the enzyme.
tion at 37C in the (A  B) medium [39], supplemented with 0.5% The optimized conditions were 3.3–3.7 M Na format, 0.1 M Na ace-
glucose and 0.1 mg/ml of each of the four amino acids L-methionine, tate (pH 3.5–4.5), 25 mM -OG prior to equilibration after mixing,
L-leucine, L-isoleucine, and L-valine. At OD436  1 the cells were and 12–15 mg/ml protein. The crystals grew as yellow needles over
harvested by centrifugation and resuspended in ten times the origi- a period of 1–2 weeks. The crystal used for collecting the MAD data
nal volume of a similar, prewarmed medium, however, with DL- had further been prepared in the presence of the reaction product
selenomethionine (200 mg/L) (Sigma) replacing the normal L-methio- orotate, added to the protein solution in 5-fold excess prior to crys-
nine. The cells soon adopted a growth rate (approximately 90 min/ tallization. The crystals belong to the space group P41212, like the
doubling), which was half of the growth rate in the regular methionine native, with very similar cell parameters, a  b  119.7 A˚ and c 
medium (about 45 min/doubling), indicating that the supply of regu- 295.97 A˚, corresponding to four molecules in the asymmetric unit.
lar methionine was used up and that they had now started to incor-
porate selenomethionine into the proteins. IPTG (0.5 mM) was added Data Collection
to the culture at OD436  0.5, and growth was continued overnight. To be able to collect data under cryogenic conditions, we soaked
The cells were harvested by centrifugation, washed in 0.9% sodium the crystals for a few seconds in a cryoprotectant containing 4.5 M
chloride, and stored frozen at20C until they were used for enzyme Na formate, 0.1 M Na acetate at the crystallization pH, and 10%
purification. glycerol. The Se edge MAD data sets used to solve the structure
Purification of SeMet-labeled dihydroorotate dehydrogenase was were collected at the FIP/BM30A beamline at the ESRF in Grenoble,
carried out as described previously [13], except that DTT (1 mM) France, using a MAR345 Image Plate detector. Data extending to
was added to the crude extract and to all active fractions in the 2.5 A˚ were collected at three wavelengths (Table 2) around the Se
subsequent chromatography steps. The final yield of SeMet-labeled edge at 165C. An oscillation of 0.5/image and an exposure time
dihydroorotate dehydrogenase was 25 mg, which is 4-fold lower of 120 s/image were used, collecting the data in sector widths of
than was seen for the dihydroorotate dehydrogenase prepared from 10. Because of the long c axis, a detector to crystal distance of
cells grown in LB medium [13]. Although the content of SeMet in 420 mm was necessary to optimize the resolution and avoid spot
the purified protein was not analyzed, we have previously shown overlaps. The data was integrated and scaled using DENZO and
that this growth procedure, with SØ6735 as background, generated SCALEPACK [41]. The main statistics for data collection and integra-
a very close to 100% replacement of methionyl residues in OMP tion are given in Table 2.
decarboxylase with selenomethionyl residues [40].
Solving the Structure
The program SOLVE [42] was used to identify the Se sites in theTruncation of DHODC at the N Terminus
structure. The data from SCALEPACK was directly inserted inEnzymes with truncations in the N-terminal part of DHODC were
SOLVE, and a unique solution with 24 sites, out of 28 possible sites,constructed by standard PCR techniques with the pyrD plasmid
was obtained, with a figure of merit of 0.57 for a resolution of 3.0 A˚.pED6 [17] as template. The upstream primer contained a cutsite for
Four of the 28 methionines in the amino acid sequence are N-ter-EcoRI, a ribosome binding sequence, a spacer sequence, and an
minal residues. The 24 sites were refined with SHARP [43]. The NCSinitiator methionine codon (ATG) fused with a sequence of 20 nucleo-
was found manually, and a mask could be calculated with NCSMASKtide residues, which was homologous with pyrD and began with the
[27]. Using the options for solvent flattening and NCS averaging incodon triplet intended to be number 2 in the truncated pyrD gene.
DM [24], we calculated the first maps, and a skeleton could beFor example, the DNA oligomer 5-CACAGAATTCCAGGAGAGTT
traced with MAPMAN [44]. The skeleton was converted into a CCATGGGAACGCCGTTTGAAGCACT-3OH was used as upstream
trace with the BONES option in O [45]. On the basis of this conver-primer to delete the codons 2–30 from the pyrD gene. The down-
sion, the individual amino acids could be inserted to the electronstream primer was always 5-CGCGGATCCATTAGATATGGGTAAC
density, with the exception of the first two N-terminal residues.GATTTC-3OH, which represented the end of the pyrD gene and
contained an artificial BamHI site. The PCR product was digested
with EcoRI and BamHI and cloned into the vector pUHE23-2 to Structure Refinement
Once the initial model was built, refinement was carried out usinggenerate plasmids similar to our expression vector, pAG1 [13], and
the entire coding region was confirmed by DNA sequencing. To CNS [46]. During the first cycles of refinement, strict NCS constraints
were used. Once the initial model was properly refined, small differ-produce the truncated proteins, the plasmids were transformed into
the E.coli strain SØ6645. Growth of the transformed strains and ences were observed for the side chains in the different molecules
in the asymmetric unit, and the NCS restraints were decreased until,preparation of extracts were performed as previously described
[13]. Purification of the truncated DHODC, lacking residues 2–30, in the final step, the four molecules were refined independently.
Water molecules were placed by the automatic water-inserting pro-was attempted by the procedure of Bjo¨rnberg et al. [13]. However,
as the protein eluted from the hydrophobic phenyl Sepharose col- cedure in CNS, without any NCS constraints. Manual rebuilding of
the model and initial insertion of the orotate and formate moleculesumn at very high ionic strength, this column gave essentially no
purification. Therefore, the active fractions from this column were was carried out with O. The final model has been refined to R 
17.8% and Rfree 21.7% in the resolution range 20–2.5 A˚.pooled, dialyzed exhaustively against 5 mM sodium phosphate (pH
7.0) containing 0.1 M Triton X-100, and applied to a Q6 column (Bio- Theφ,peptide angles of all residues fall into the allowed regions
of the Ramachandran plot [47]. All residues are well defined in theRad), where it bound to the top of the column as a very concentrated
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electron density, except for the two N-terminal residues in molecules Purification and characterization of dihydroorotate dehydroge-
nase A from Lactococcus lactis, crystallization and preliminaryB, D, and E. Some side chains are refined with an occupancy of
less than 1.0, those being mainly solvent-exposed residues. Seven X-ray diffraction studies of the enzyme. Protein Sci. 5, 852–856.
13. Bjo¨rnberg, O., Gru¨ner, A.C., Roepstorff, P., and Jensen, K.F.amino acids are refined in double conformations (chain A: Gln12
and Asp153; chain B: Mse50 and Gln205; chain E: Arg39, Asn48, (1999). The activity of Escherichia coli dihydroorotate dehydro-
genase is dependent on a conserved loop identified by se-and Asn199) and also the N-terminal-situated orotate molecule of
chain A. All four molecules of the asymmetric unit contain three cis- quence homology, mutagenesis, and limited proteolysis. Bio-
chemistry 38, 2899–2908.peptide bonds, Gly85-Thr86, Lys97-Pro98, and Ala244-Thr245.
14. Andersen, P.S., Martinussen, J., and Hammer, K. (1996). Se-
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